Trials / Completed
CompletedNCT00226980
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
A Phase II Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thalidomide | |
| DRUG | Capecitabine |
Timeline
- Start date
- 2002-10-01
- Primary completion
- 2005-07-01
- Completion
- 2006-07-01
- First posted
- 2005-09-27
- Last updated
- 2009-04-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00226980. Inclusion in this directory is not an endorsement.